D. Jeffrey Keyser

CIK: 0001393516

Transaction Breakdown

Open Market Buys (P)1 (14.3%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (57.1%)

Compensation grants

Other (G, F, J, C, D, …)2 (28.6%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

LTRN

Lantern Pharma Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (7 total)

LTRN
Lantern Pharma Inc.
May 12, 2026
Purchase(P)
Direct
48.5K shares at avg. $2.06$100K
LTRN
Lantern Pharma Inc.
Jan 9, 2026
Award(A)
Stock Option (Right to Buy)
Direct
28.8K shares-
LTRN
Lantern Pharma Inc.
Jan 9, 2026
Award(A)
Stock Option (Right to Buy)
Direct
25K shares-
LTRN
Lantern Pharma Inc.
Nov 4, 2021
Disposition(D)
Stock Option (Right to Buy)
Direct
3.2K shares-
LTRN
Lantern Pharma Inc.
Nov 4, 2021
Award(A)
Stock Option (Right to Buy)
Direct
3.2K shares-
LTRN
Lantern Pharma Inc.
Jun 15, 2020
Disposition(D)
Stock Option (Right to Buy)
Direct
9.1K shares-
LTRN
Lantern Pharma Inc.
Jun 15, 2020
Award(A)
Stock Option (Right to Buy)
Direct
9.1K shares-

		Type	Shares	Price		Ownership
May 12, 2026	LTRN Lantern Pharma Inc.	Purchase(P)	48,544	$2.06	$100,001	Direct
Jan 9, 2026	LTRN Lantern Pharma Inc.	Award(A) Stock Option (Right to Buy)	28,844	-	-	Direct
Jan 9, 2026	LTRN Lantern Pharma Inc.	Award(A) Stock Option (Right to Buy)	25,000	-	-	Direct
Nov 4, 2021	LTRN Lantern Pharma Inc.	Disposition(D) Stock Option (Right to Buy)	3,200	-	-	Direct
Nov 4, 2021	LTRN Lantern Pharma Inc.	Award(A) Stock Option (Right to Buy)	3,200	-	-	Direct
Jun 15, 2020	LTRN Lantern Pharma Inc.	Disposition(D) Stock Option (Right to Buy)	9,135	-	-	Direct
Jun 15, 2020	LTRN Lantern Pharma Inc.	Award(A) Stock Option (Right to Buy)	9,135	-	-	Direct

1-7 of 7 transactions

About KEYSER D JEFFREY

KEYSER D JEFFREY (SEC CIK 0001393516) files insider reports with the SEC as Director of Lantern Pharma Inc. (LTRN).

Signal8 holds 3 ownership filings by KEYSER D JEFFREY, all Form 4s, filed between Sep 23, 2025 and May 14, 2026. Those filings report 7 transactions, from Jun 15, 2020 to May 12, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on KEYSER D JEFFREY's filings is in DALLAS, TX.

Recent filings by KEYSER D JEFFREY

May 12, 2026: Open-market purchase of LTRN shares (Form 4, code P).
Jan 9, 2026: Grants or awards of LTRN derivative securities (2 lines, Form 4, code A).
Nov 4, 2021: Disposition to issuer transaction of LTRN derivative securities (Form 4, code D).
Nov 4, 2021: Grant or award of LTRN derivative securities (Form 4, code A).
Jun 15, 2020: Disposition to issuer transaction of LTRN derivative securities (Form 4, code D).

Other insiders filing for Lantern Pharma Inc. (LTRN)

Schalop Lee Troy, Director
Maccecchini Maria-Luisa, Director
Chandru Vijay, Director
Silberstein David S., Director
Margrave David R., Chief Financial Officer
Bhatia Kishor G., Chief Scientific Officer

How to read Form 4 transaction codes